#ACC22 [Ainda não publicado] – Estudo randomizado | Mavacantem reduz a necessidade de intervenção cirúrgica em pacientes com cardiomiopatia hipertrófica obstrutiva.

VALOR-HCM: Mavacamten Significantly Reduces Need For Surgical Intervention in Patients With Obstructive HCM – American College of Cardiology

Comentários:

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM – TCTMD

Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy – VALOR-HCM – American College of Cardiology

Trial shows drug effective in nearly 80% of patients with hypertrophic cardiomyopathy – Cleveland Clinic

Conteúdo relacionado: #ESCCongress – Randomized trial: Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy

Comentário no Twitter

ICYMI: The VALOR-HCM trial at #ACC22 showed that mavacamten improved symptoms & significantly reduced eligibility for needing septal reduction therapy (SRT) among symptomatic patients with obstructive #cvHCM. Check out the Trial Summary here: https://t.co/fXVp8H0bw5 @DLBHATTMD pic.twitter.com/f0gPp9dNX8

— American College of Cardiology (@ACCinTouch) April 2, 2022